All Outputs (2)

The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects (2019)
Journal Article
Al-Qaissi, A., Alqarni, S., Javed, Z., Atkin, S. L., Sathyapalan, T., Vince, R., & Madden, L. A. (2019). The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. Endocrine, https://doi.org/10.1007/s12020-019-02059-9

© 2019, The Author(s). Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals... Read More about The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects.

The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome (2019)
Journal Article
Dawson, A. J., Sathyapalan, T., Vince, R., Coady, A. M., Ajjan, R. A., Kilpatrick, E. S., & Atkin, S. L. (2019). The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome. Frontiers in endocrinology, 10(APR), Article 189. https://doi.org/10.3389/fendo.2019.00189

Background: Polycystic ovary syndrome (PCOS) is associated with an adverse cardiovascular risk profile including a prothrombotic state. Exenatide has been shown to be effective at improving insulin sensitivity and weight loss in PCOS; therefore this... Read More about The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome.